Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
|Articles|August 24, 2015
Dr. Tripathy on the Development of Palbociclib in Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.
Advertisement
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.
Advertisement
Related to this article
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Brianne Whitley, CNP, of Dana-Farber, shares strategies for hot flashes, sexual health, survivorship planning, and clinical trial access for men.
Dana-Farber's Brianne Whitley, CNP, details red-flag symptoms, ER-positive biology, and why every man with breast cancer needs a genetic referral.
Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
What Oncology Nurses Need to Know About ADCs in Breast Cancer
2
AI Breast Cancer Risk Models Guide Triage and Nurse-Led Patient Counseling
3
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-H Solid Tumors
5